Logo image of SLDB

SOLID BIOSCIENCES INC (SLDB) Stock Fundamental Analysis

NASDAQ:SLDB - Nasdaq - US83422E2046 - Common Stock - Currency: USD

5.03  +0.16 (+3.29%)

After market: 4.9105 -0.12 (-2.38%)

Fundamental Rating

3

Overall SLDB gets a fundamental rating of 3 out of 10. We evaluated SLDB against 555 industry peers in the Biotechnology industry. SLDB has a great financial health rating, but its profitability evaluates not so good. SLDB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SLDB has reported negative net income.
SLDB had a negative operating cash flow in the past year.
SLDB had negative earnings in each of the past 5 years.
In the past 5 years SLDB always reported negative operating cash flow.
SLDB Yearly Net Income VS EBIT VS OCF VS FCFSLDB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

SLDB has a Return On Assets (-40.59%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -47.41%, SLDB is doing good in the industry, outperforming 66.31% of the companies in the same industry.
Industry RankSector Rank
ROA -40.59%
ROE -47.41%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-48.03%
ROE(3y)-69.2%
ROE(5y)-61.82%
ROIC(3y)N/A
ROIC(5y)N/A
SLDB Yearly ROA, ROE, ROICSLDB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLDB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLDB Yearly Profit, Operating, Gross MarginsSLDB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, SLDB has more shares outstanding
The number of shares outstanding for SLDB has been increased compared to 5 years ago.
SLDB has a better debt/assets ratio than last year.
SLDB Yearly Shares OutstandingSLDB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLDB Yearly Total Debt VS Total AssetsSLDB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of 1.00, we must say that SLDB is in the distress zone and has some risk of bankruptcy.
SLDB's Altman-Z score of 1.00 is fine compared to the rest of the industry. SLDB outperforms 65.23% of its industry peers.
There is no outstanding debt for SLDB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1
ROIC/WACCN/A
WACCN/A
SLDB Yearly LT Debt VS Equity VS FCFSLDB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 10.89 indicates that SLDB has no problem at all paying its short term obligations.
SLDB has a Current ratio of 10.89. This is amongst the best in the industry. SLDB outperforms 80.36% of its industry peers.
A Quick Ratio of 10.89 indicates that SLDB has no problem at all paying its short term obligations.
SLDB has a Quick ratio of 10.89. This is amongst the best in the industry. SLDB outperforms 80.72% of its industry peers.
Industry RankSector Rank
Current Ratio 10.89
Quick Ratio 10.89
SLDB Yearly Current Assets VS Current LiabilitesSLDB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.11% over the past year.
EPS 1Y (TTM)24.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SLDB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.01% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.76%
EPS Next 2Y14.15%
EPS Next 3Y11.48%
EPS Next 5Y14.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLDB Yearly Revenue VS EstimatesSLDB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2025 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
SLDB Yearly EPS VS EstimatesSLDB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLDB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLDB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLDB Price Earnings VS Forward Price EarningsSLDB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLDB Per share dataSLDB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.15%
EPS Next 3Y11.48%

More info and screens

0

5. Dividend

5.1 Amount

SLDB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLID BIOSCIENCES INC

NASDAQ:SLDB (7/3/2025, 8:09:27 PM)

After market: 4.9105 -0.12 (-2.38%)

5.03

+0.16 (+3.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners87.06%
Inst Owner Change116.86%
Ins Owners0.56%
Ins Owner Change0.37%
Market Cap389.93M
Analysts86.32
Price Target16.43 (226.64%)
Short Float %12.39%
Short Ratio4.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.84%
Min EPS beat(2)-21.61%
Max EPS beat(2)-4.07%
EPS beat(4)1
Avg EPS beat(4)-7.95%
Min EPS beat(4)-21.61%
Max EPS beat(4)9.9%
EPS beat(8)5
Avg EPS beat(8)0.55%
EPS beat(12)7
Avg EPS beat(12)-3.07%
EPS beat(16)10
Avg EPS beat(16)-0.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.05%
PT rev (3m)-5.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.15%
EPS NY rev (1m)4.08%
EPS NY rev (3m)4.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-2.99
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-1.39
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS3.8
TBVpS3.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.59%
ROE -47.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-48.03%
ROE(3y)-69.2%
ROE(5y)-61.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.89
Quick Ratio 10.89
Altman-Z 1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.22%
Cap/Depr(5y)55.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.81%
EPS Next Y29.76%
EPS Next 2Y14.15%
EPS Next 3Y11.48%
EPS Next 5Y14.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.68%
EBIT Next 3Y-12.76%
EBIT Next 5YN/A
FCF growth 1Y-5.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.17%
OCF growth 3YN/A
OCF growth 5YN/A